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Abstract 
Treatment of glioblastoma and other diseases in the brain is especially challenging due to the 
blood-brain barrier, which effectively protects the brain parenchyma. In this study we show for the 
first time that cabazitaxel, a semi-synthetic derivative of docetaxel can cross the blood-brain barrier 
and give a significant therapeutic effect in a patient-derived orthotopic model of glioblastoma. We 
show that the drug crosses the blood-brain barrier more effectively in the tumor than in the healthy 
brain due to reduced expression of p-glycoprotein efflux pumps in the vasculature of the tumor. 
Surprisingly, neither ultrasound-mediated blood-brain barrier opening (sonopermeation) nor drug 
formulation in polymeric nanoparticles could increase either accumulation of the drug in the brain 
or therapeutic effect. This indicates that for hydrophobic drugs, sonopermeation of the blood brain 
barrier might not be sufficient to achieve improved drug delivery. Nonetheless, our study shows 
that cabazitaxel is a promising drug for the treatment of brain tumors. 
Key words: cabazitaxel, glioblastoma, orthotopic model, sonopermeation 
Introduction 
Glioblastoma (GBM) represents one of the worst 
prognoses among cancers, with a median survival of 
14.6 months [1]. GBM typically exhibits rapid, 
invasive growth, insensitivity to radiation and 
chemotherapy and often an intact blood brain barrier 
(BBB)[2, 3]. The standard therapy for GBM consists of 
a combination of surgery, radiotherapy and 
temozolomide. Partly due to the intact BBB, the 
selection of effective drugs is highly limited. 
Temozolomide is a small lipophilic drug known to 
cross the BBB to some extent [1, 4], but methods to 
deliver this drug more efficiently across the BBB are 
sought [5]. 
Cabazitaxel (cab) (Jevtana®, Sanofi-Aventis) is a 
highly potent taxane used as a second line treatment 
in docetaxel-resistant prostate cancer presumably due 
to its lower affinity to the efflux transporter 
P-glycoprotein (P-gp)[6, 7]. It has been evaluated 
without success in a phase II study for effect in 
temozolomide refractory glioma (clinicaltrials.gov 
NCT 01866449).  
One of the most promising methods for drug 
delivery across the BBB is targeted sonopermeation 
[8-11] where focused ultrasound (FUS) and exogenous 
microbubbles (MBs) are used to enable permeation 
through the BBB, presumably by disrupting the tight 
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junctions between endothelial cells and thereby 
increasing extravasation of drugs [12], and/or 
downregulating P-gp [13-16]. The effects of 
sonopermeation are generally considered safe and 
transient, but a recent study has challenged this view 
[17]. Especially for GBM, which is often a localized 
disease, targeting by FUS is promising for increased 
local drug delivery, a strategy that is also currently 
under evaluation in clinical trials [18, 19]. 
While using FUS and MBs for BBB opening is 
quite well established, it is not clear how far into the 
brain parenchyma the method can deliver various 
forms of drugs. It has been hypothesized that 
sonopermeation can be especially promising in the 
combination with macromolecules and 
nanomedicines as these are unable to extravasate 
from intact vessels. Nanomedicines also have the 
potential advantages of reducing side effects, 
controlling drug delivery and allowing for delivery of 
pharmaceuticals such as hydrophobic drugs, proteins 
and nucleic acids[20]. 
We have previously presented an inhouse 
technology consisting of biodegradable poly (alkyl 
cyanoacrylate) (PACA) nanoparticles (NPs) that can 
be used to stabilize MBs [21, 22], and used them to 
deliver the NPs both to solid tumors [23] and across 
the BBB [24, 25]. In the current study we aimed to treat 
mice with a patient derived xenograft (PDX)-model of 
GBM that closely resembles the human disease 
[26-28]. The model is invasive and independent of 
angiogenesis, suggesting that the BBB should be intact 
and present a barrier to drug delivery. We 
hypothesized that cab can be a useful drug in the 
treatment of GBM and investigated the effect of 
sonopermeation of the BBB on both the delivery of cab 
and cab-loaded NPs (cab-NPs). 
Materials and methods 
NPs, NPMBs and Cab 
Empty or cab-loaded poly(2-ethyl butyl 
cyanoacrylate) (PEBCA) NPs (cab-NPs) and NP 
stabilized microbubbles (NPMBs) were synthesized as 
described previously [21, 23, 24]. Briefly, the NPs were 
made in a one-step mini emulsion polymerization 
where the water phase contained the surfactants Brij 
L23 (10 mM, 23 PEG units, MW 1225, Sigma- Aldrich) 
and Kolliphor HS15 (10 mM, 15 PEG units, MW 960, 
Sigma-Aldrich) in 0.1 M HCl and the oil phase 2-ethyl 
butyl cyanoacrylate, Miglyol 812 (co-stabilizer, 
Cremer) methane sulphonic acid (Sigma-Aldrich), azo 
bis-dimethyl valeronitrile (V65, oil-soluble radical 
initiator, Waco) and 10% w/v cab for the drug loaded 
NPs. The miniemulsion was formed by sonicating for 
3 minutes on ice (6 x 30 second intervals, 60% 
amplitude, Branson Ultrasonics digital sonifier 450). 
The NPs were dialyzed to remove unreacted 
surfactants. NPMBs were made by mixing 1% w/v 
NPs with 0.5% w/v Casein (Sigma) in 0.9% PBS using 
an Ultra Turrax (Branson Ultrasonics). The clinical 
formulation of cab was made following the protocol 
for Jevtana®. Cab (TXD-258, Biochempartner Co. 
Ltd.,) was dissolved to 40 mg/ml in Tween-80 
(Sigma-Aldrich) and further dissolved 1:4 in 13% 
ethanol.  
Size and size distribution of the NPs and cab was 
measured by dynamic light scattering (DLS, Zetasizer 
Nano ZS, Malvern Instruments). Drug loading was 
measured by LC-MS/MS as described previously 
[23]. NPMBs were imaged in a Countess cell counting 
chamber (ThermoFisher) and analyzed for size, 
concentration and size distribution with ImageJ. NPs 
and NPMBs were imaged and visually inspected by 
scanning electron microscopy on either a SEM 
APREO (NPs) (FEI), or a S(T)EM (NPMBs) (Hitachi). 
The NPMBs were sputter coated with 5 nm gold prior 
to imaging. 
Cell culture 
The GBM cell line P3 was derived from a patient 
biopsy and has been characterized previously [29]. 
Cells were cultured in Neurobasal medium (Gibco), 
supplemented with B27 (20 μl/ml, Gibco), 
GlutaMax-1 (10 μl/ml, Gibco), fibroblast growth 
factor-2 (FGF-2, 20 ng/ml, Peprotech) and Heparin 
(64 IU/ml, LEO). 
In vitro toxicity 
For in vitro toxicity, cells were grown in 96well 
plates (10000 cells/well) for 4 days before cab-NPs, 
empty NPs or cab was added to the wells at 
concentrations ranging from 0.003 ng/ml to 200 
ng/ml. Cells were incubated for 72 hours. 
Cytotoxicity was then measured by the AlamarBlue 
assay (Thermo Fisher Scientific). AlamarBlue was 
diluted 1:10 in cell medium and added to the wells. 
After 4 hours incubation, fluorescence at ex/em 
550/590 nm was measured using a plate reader 
(SpectraMax i3, Molecular Devices).  
Animals and tumor inoculation 
Female Nod/SCID mice and Balb/c nude mice 
where purchased from Janvier Labs at 8 weeks of age 
and housed in specific pathogen free conditions at 
22–23 °C, 50–60% relative humidity. The mice had free 
access to food and sterile water. All experimental 
procedures were approved by the Norwegian Animal 
Research Authorities.  
Before inoculation of the glioma cells, the 
animals were anaesthetized using isoflurane (~2% in 
78% medical air/20% O2). Tamgesic (1:10, 0.1 ml/20 
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g) was given as local analgesic subcutaneously on the 
scalp. The skin was sterilized by ethanol and a 1 cm 
sagittal incision was made to expose the bregma. A 
hole was drilled at the coordinates A +1, L -2 and V 
-3.5 mm in relation to bregma. 5 µl cell suspension 
(200 000 cells) was aspirated into a 25 µl Hamilton 
syringe (Model 1702 N). The syringe was mounted 
onto a stereotactic frame and inserted into the brain 
slowly for 4 mm and then retracted 0.5 mm, before the 
injection. The injection was performed over 3 minutes 
and 2 minutes later the syringe was slowly retracted. 
The scalp was sutured and Marcain (1:5, 0.04 ml/20g) 
was injected subcutaneously on the scalp for 
long-term analgesia, while 2 mL saline was injected 
subcutaneously for hydration purposes during the 
recovery. 
Monitoring / MRI imaging 
Magnetic resonance imaging (MRI) was 
performed on a 7.05 T horizontal bore magnet 
(Biospec 70/20 Avance III, Bruker Biospin) with an 86 
mm volume resonator for RF transmission and a 
phased array mouse brain surface coil for reception. 
From week three post inoculation, the animals were 
scanned on a weekly basis to evaluate tumor 
development using a T2-RARE weighted protocol. 
The animals were anesthetized using isoflurane (~2% 
in 78% medical air/20% O2). 
T2-RARE: TE/TR 54/2000 ms, RARE factor 16, 
zero fill acceleration of 1.3, 14 averages, lasting 5 
minutes and 36 seconds. The geometry of the MR 
sequence had a field of view of 20 mm x 20 mm, 
matrix size of 200x200 and 9 slices á 1 mm. 
Treatment 
Treatment was initiated after 5 weeks when the 
tumors had reached approximately 15 mm3. The 
animals were randomly divided into four groups and 
treated with 1: cab-NPMB and FUS (N=3), 2: cab, 
empty NPMB and FUS (N=4), 3: cab (N=4), 4: Saline 
control (N=4), as visualized in Figure 1. The animals 
received two weekly treatments. In group 1 the 
cab-NPMBs were injected immediately before FUS, in 
group 2 free cab was injected followed by empty 
NPMBs, before FUS. In a separate set of animals the 
tumors were allowed to grow for one additional week 
to get tumors with sizes similar to the average in the 
treatment groups and the animals were euthanized 3 
hours after treatment to quantify cab content in the 
brain (3 mice / group). In this part of the study three 
balb/c nude mice where included due to challenges 
with delivery of NOD/Scid mice. Tumors grew 
similarly in this mouse strain. 
In group 1 and 2, MRI-guided FUS was used to 
open the BBB/blood-tumor barrier (BTB) in and 
around the tumor. MRI images for guiding was 
acquired as described above (similarly as for 
monitoring growth), but a larger phased array rat 
brain surface coil, placed on top of the animal, was 
used for reception as the animals were laying in a 
supine position. For T2-RARE, the same sequence was 
used, and Fast-Low Angle Shot (FLASH) was used to 
evaluate the BBB-opening by extravasation of the 
gadolinium (Gd)-contrast agent Omniscan (GE 
Healthcare) into the brain parenchyma.  
FLASH: Flip angle of 40°, TE/TR 3.5/200 ms, 
zero fill acceleration of 1.3, 12 averages, lasting 2 
minutes and 22 seconds. The geometry of the MR 
sequence had a field of view of 20mmx20 mm, matrix 
size of 200x200 and 9 slices á 1 mm.  
The ultrasound equipment was a RK300 (FUS 
Instruments) with a 1.1 MHz transducer. Four 
sonication targets in a 2x2 matrix (distanced 1.5 mm 
apart), were selected on each animal to cover the 
tumor. The sonication lasted for 6 minutes with a 
pulse repetition frequency of 1 Hz, pulse length of 
10000 cycles and an estimated in situ pressure of 0.32 
MPa. The attenuation through the mouse skull was 
15%, measured in previous experiments [24]. After 
injection of cab (50 µl, 10 mg/kg diluted in saline) 
through the tail vein, MBs were injected via the tail 
vein as 3x 50 µl bolus injections after 0, 2 and 4 
minutes. Post treatment, a bolus injection of Gd was 
injected to evaluate the BBB opening. 
Following the first treatment, the animals were 
imaged for assessment of tumor size weekly for four 
weeks. Then the animals in the control group had to 
be euthanized due to the tumor size, and animals in 
all groups were euthanized. 
Mass spectrometry (MS)-analysis of cab 
accumulation 
To quantify delivery of cab to the healthy brain 
and tumor, 3 hours after the treatment the mice were 
killed and the brains removed. The brains were 
divided in two (healthy and tumor-bearing 
hemisphere) and weighed. The two hemispheres were 
manually cut into pieces and digested with an 
enzyme buffer. The enzyme buffer consisted of 
Dulbecco's Modified Eagle Medium (DMEM, Thermo 
Fisher Scientific) with 1% (v/v) 
penicillin-streptomycin (Sigma-Aldrich) giving a final 
concentration of 100 U/ml penicillin and 100 µg/ml 
streptomycin, 0.125 mg/ml papain (Merck), 2.5 
mg/ml trypsin (Sigma-Aldrich), 0.8 mg/ml 
collagenase (Sigma-Aldrich), 0.69 mg/ml 
hyaluronidase (Sigma-Aldrich) and 1% (v/v) Triton 
X-100 (Sigma-Aldrich). Freshly prepared enzyme 
buffer was added at 1 ml per 50 mg tissue. The 
samples were heated to 37 °C for 72 hours with 
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vortexing once a day, until the tissue was completely 
dissolved. The tissue digests were diluted 10x in 
acetone before centrifugation; this has the dual effect 
of both precipitating proteins and other 
macromolecules, thus cleaning up the sample, and 
making sure all cab is solubilized. Internal standard 
(hexadeuterated cab) dissolved in acetone was added 
to a final concentration of 10 ng/ml during the 
acetone dilution to correct for possible matrix effects.  
Cab was quantified by LC-MS/MS, using an 
Agilent 1290 HPLC system coupled to an Agilent 6490 
triple quadrupole MS. The HPLC column was an 
Ascentis Express C8, 75x2.1 mm, 2.7 µm particle size 
with a 5x2.1 mm guard column of the same material 
(Sigma-Aldrich), run at 40 °C. Eluent A was 25 mM 
formic acid in water and eluent B was 100% methanol, 
and flow rate was 0.5 ml/minute. The mobile phase 
gradient was isocratic at 55% eluent B for 1.5 minute, 
then from 55% to 80% B over 1 min, followed by 
1 minute washout time and subsequently column 
re-equilibration. Injection volume was 5.0 µl. MS 
detection was in positive ESI mode (Agilent 
Jetstream) quantified in multiple reaction monitoring 
(MRM) mode using the transition m/z 858.3  577.2. 
The parent ion was chosen to be the Na adduct as this 
gave the best sensitivity. Similarly, the 
hexadeuterated internal standard was detected on the 
864.4  583.2 transition. Analytes were run at 380 V 
fragmentor and 20 V collision energy. 
Reference standards were used for accurate 
quantification. The unlabeled cab standard was the 
same as used for synthesis. Hexadeuterated cab 
internal standard was purchased from Toronto 
Research Chemicals (99.6% isotopic purity). 
Standards were dissolved in acetone and were used to 
build an unlabeled standard series spanning at least 
five concentration points. 
Histology and P-gp staining 
28 days after first treatment all animals were 
euthanized and the brains were embedded in 
formalin and H&E-stained for histopathological 
assessment. In addition, the sections were stained for 
P-gp efflux pump expression using an anti-P-gp 
antibody (EPR10364-57, Abcam, 1:200 dilution) 
followed by incubation with HRP (horseradish 
peroxidase) Rabbit EnVision–Polymer and DAB+ 
(3,3'-Diaminobenzidine) Chromogen (both from 
DAKO). Stitched images of entire brain sections were 
acquired on a Zeiss LSM 800 at 20x magnification. 
Images were acquired in bright field mode using 
built-in functions for color correction and uneven 
illumination correction. For analysis of P-gp 
expression, 8 region of interests (ROIs) of 840x1120 
pixels were randomly chosen from each of the areas: 
1, Healthy: The hemisphere without tumor. 2, Tumor 
proximity: Tumor-bearing hemisphere but outside the 
tumor. 3, Tumor periphery: Areas in the tumor border 
containing a mix of healthy and tumor cells. 4, Tumor 
core: Areas within the tumor core. The areas were 
then analyzed for cell density and P-gp expression 
using the InForm® software (Perkin Elmer) by 
supervised training of the software to recognize 
nuclei and DAB-stained P-gp. 
Data Analysis 
Data analysis and statistics were performed in 
Graphpad Prism7®. Throughout the figures error 
bars show standard deviation and significance is 
denoted as * = p<0.05, ** = p<0.01, *** = p<0.001 and 
**** =p<0.0001. 
 
 
Figure 1: Studied treatment groups. 
 
Results 
Cab was formulated either as Jevtana, i.e. 
dissolved in Tween 80 and ethanol, or in PEBCA NPs. 
The cab-NPs had a diameter of 153 nm, polydispersity 
index (PDI) of 0.19, zetapotential of – 1.8 mV and a cab 
loading capacity of 8.9% w/w (Figure 2). The empty 
NPs had a diameter of 162 nm, PDI of 0.15 and 
zetapotential of -2 mV. Jevtana forms 
micelles/clusters in aqueous solutions with a size 
around 10nm (Figure 2). The two formulations had 
similar effect on glioma cells in vitro with IC50 values 
around 20 ng/ml (Figure 2B) which is approximately 
1000 times lower than empty NPs [30].  
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Figure 2: Characterization of the NP and MB platform. A: Diameter of cab, cab-NPs and cab-NPMBs by DLS or microscopy. B: Effect of cab, cab-NPs and empty NPs 
on patient derived glioblastoma cells in vitro (n=2), error bars represent standard deviation. C: SEM image of the cab-NPs and D; SEM image of the empty NPMBs. 
 
Figure 3: FUS mediated BBB-opening. A: FLASH images of the mouse brain before Gd injection, after Gd injection and after FUS treatment and Gd injection. B: 
Opening of BBB and extravasation of Gd. Signal from the tumor was compared to a mirrored ROI in the non-treated hemisphere, each line shows one animal, error 
bars show standard deviation of signal increase from three different sections of the tumor. The opening was measured in 5 animals. C: Variation between mice in BBB 
opening as measured by Gd extravasation. Pre Gd: Before injection of Gd. Post Gd: After injection of Gd, but before FUS treatment. Post FUS: After FUS treatment 
and with a new bolus injection of Gd. 
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To investigate the leakiness of the BBB/BTB and 
the effect of FUS, we injected Gd contrast agent both 
before and after FUS and cab treatment. If the BBB or 
BTB was leaky, MRI would reveal a Gd-signal 
increase before FUS exposure. We observed no 
leakiness either in the healthy brain or in the tumor 
(Figure 3). However, after sonication and BBB 
opening, considerable signal increase could be 
observed in the sonicated region in all treated animals 
(Figure 3). 
Following the observation that the BBB was 
intact also in the tumor, and not leaky to the MRI 
contrast agent, we aimed to investigate whether cab 
could cross the BBB and delay tumor progression. We 
also aimed to test if delivery of cab could be increased 
by formulation in NPs and permeating the BBB using 
FUS. The mice were injected intravenously with cab 
formulated as Jevtana or PACA NPMBs, and the BBB 
was opened using FUS and NPMBs (groups 
visualized in Figure 1.) A subgroup of animals was 
euthanized after 3 hours and the extracts from the 
brains were analyzed with LC-MS/MS. Interestingly, 
it was found that cab, regardless of delivery method 
(cab +/- FUS or cab-NPMBs + FUS) accumulated 
more in the hemisphere with the implanted tumor 
compared to the healthy hemisphere (Figure 4). A 
strong, positive correlation between amount of cab in 
tumor tissue and healthy tissue was observed (Figure 
4B), and the tumor tissue had approximately 4 times 
more cab than healthy tissue. The correlation indicates 
that properties of the individual mice are decisive for 
the delivery of cab to the tumor (Figure 4B). There was 
a weak indication of less cab in the sonicated tumors 
(Figure 4A), indicating that BBB-opening could 
increase reflux of the drug back to the blood stream. 
After finding that cab crossed the BTB to a larger 
extent than the BBB, the therapeutic potential of the 
drug was evaluated by treating NOD/SCID mice with 
the implanted PDX-glioma. Such experiments would 
reveal whether BBB opening, although not able to 
increase the accumulation/retention of the drug in the 
brain, could give improved therapeutic effect due to 
other mechanisms such as increased penetration into 
the brain parenchyma. All three treatment groups 
(cab-NP + FUS, cab + FUS, cab) had a significant 
therapeutic effect compared to the control group, but 
there was no difference between the treated groups 
(Figure 5). The treatment delayed the tumor growth 
significantly with the tumors reaching only a third of 
the size of the control tumors 3 weeks after the last 
treatment, i.e. all treated groups had an average size 
of approximately 70 mm3 compared to 250 mm3 in the 
control group (Figure 5).  
At the endpoint of the treatment study, brains 
were sectioned and the tumor histology was 
evaluated and used to assess cell density and P-gp 
expression. 
Since efflux pumps in the brain blood vessels are 
known to be an important barrier for delivery of 
many molecular drugs that would otherwise pass 
through the endothelial cells, and the tumor model 
was found to have a non-leaky phenotype when 
imaged by contrast enhanced MR imaging (Figure 3), 
we stained for P-gp in the brain sections (Figure 6). It 
was found that the level of P-gp-expression was 
down-regulated in the tumor blood vessels compared 
to healthy vessels, and the tumor cells did not express 
detectable levels of the efflux pump. Moreover, a 
slight trend suggesting a correlation between 
P-gp-expression in the tumors and treatment outcome 
was observed, but the correlation was not significant 
(Figure 6C). Far higher cellular density was measured 
in the tumor compared to the healthy brain (Figure 
6D), but no indication of correlation between cellular 
density and treatment outcome was found (Figure 
6E). There was no significant change in P-gp 
expression in FUS 
treated animals (Figure 
6F). In compliance 
with the correlation 
between cab in the 
right and left 
hemisphere (Figure 
4B), and the possible 
connection between 
P-gp expression and 
tumor size (Figure 6C), 
there was a significant 
correlation between 
P-gp expression in the 
healthy hemisphere 
and the tumor (Figure 
6G). 
 
Figure 4: LC-MS/MS-analysis of cab in the brain and tumor of treated animals. A) Accumulation of cab in the tumor and healthy 
sides of the brain, mean of 3 animals in each group, error bars show standard deviation. B) Correlation between cab 
accumulation for all groups in the healthy and tumor-implanted hemisphere for the same 9 animals.  
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Figure 5: Therapeutic effect of cab. A: Representative tumor sizes at the end of the study. B: Average growth curves with standard deviation (N=3-4 per group). 
Arrows show treatments.  C: Statistical comparison of all the treated animals compared to the non-treated controls. D: Individual growth curves.  
 
Figure 6: Expression of P-pg and cell density in the brain and tumor. A: Histology of the tumor (upper panel) and healthy area in the opposite hemisphere (lower 
panel). Bright field microscopy image (left) and result after automated segmentation into nuclei (blue), P-gp (brown) and other (green) B: P-gp expression in the 
healthy part of the brain and in the areas close to or in the tumor after automatic segmentation. C: Correlation of P-gp level in the tumor compared to tumor size 
at study completion. Each point show mean from one animal and error bars show standard deviation from 8 ROI’s in the tumor. D: Area fraction of nuclei in the 
different areas, highest p-value compared to all other groups is shown. E: Area fraction of nuclei plotted against the final size of the tumor upon study completion. Each 
point shows one mean from 8 ROI’s in the tumor and one animal. F: P-gp expression in sonicated and non-sonicated tumors, n=4 in each group. G: Correlation 
between P-gp expression in the healthy hemisphere and P-gp expression in the tumor. 
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Discussion 
Cab is a novel taxane that is reported to cross the 
BBB and has been suggested as a candidate for 
medication of primary tumors or metastases to the 
brain [31-33]. It has been shown to exhibit effect 
against in vitro glioma models [34] and in patient 
derived pediatric brain tumors [35], but to our 
knowledge never before tested in PDX-models of 
GBM. The drug is not in clinical use for treatment of 
brain tumors, but is approved as a second line 
treatment to docetaxel for castration resistant prostate 
cancer [36]. The use is generally hampered by severe 
adverse effects (primarily neutropenia) [37], but it has 
been demonstrated with multiple different cytostatic 
drugs that formulation in nanomedicines can 
ameliorate this toxicity [20]. However, encapsulation 
in NPs will change the biodistribution, and 
potentially impede crossing of the BBB. We have 
previously shown that the NPs used in this study do 
not significantly cross the intact BBB [24]. In the 
present study we report that the drug formulated 
either as used in the clinic today, or combined with 
FUS and MBs or in polymeric NPMB combined with 
FUS delay the growth of PDX- glioma to the same 
extent. Consistent with this, the MS measurement 
revealed that there was no significant difference in the 
accumulation of cab in the gliomas. Interestingly, the 
tumors did not show enhancement in contrast 
enhanced MRI prior to FUS treatment showing that 
the BBB was intact prior to FUS treatment and in the 
control group receiving cab only. 
The efficient delivery of cab indicates that the 
drug is not effluxed back to the blood by P-gp. Cab is 
a substrate of P-gp, although at lower affinity than the 
other taxanes [38] and it is only able to cross the BBB 
to a limited degree and after saturation of the P-gp 
pumps [32]. The low amount of P-gp on endothelial 
cells in the tumor compared to healthy blood vessels, 
can explain the promising therapeutic response of cab. 
Consistent with this, we found indications that higher 
P-gp expression resulted in lower therapeutic effect 
and individual differences in P-gp expression in both 
BBB and BTB is the most likely explanation for the 
high correlation between cab accumulation in the 
healthy and tumor hemisphere. Why these genetically 
similar animals differ in P-gp expression is not 
known.  
In order to compare the potential therapeutic 
effect of cab both in free and NP form, we compared 
the two after opening the BTB with FUS in the 
presence of MBs. FUS in combination with MBs is 
reported in several papers to create gaps between the 
endothelial cells or in the cell membrane, and allow 
for transport into the brain interstitium [8, 39]. The 
role of P-gp in the efflux of the drug from the brain 
after BBB opening is not clear and could in principle 
be of limited importance once the NP/drug is 
deposited in the brain parenchyma and out of reach 
for the endothelial cells. However, this depends on 
how far from the blood vessels the drug travels after 
BBB opening. It is surprising that although 
sonopermeation of the BBB was confirmed by 
Gd-signal increase due to extravasation of the 
MRI-contrast agent, the FUS treatment did not 
increase accumulation of cab in any formulation. 
Hence, the differences between the formulations of 
cab and Gd, e.g. size, hydrophobicity and affinity for 
P-gp, means that Gd extravasation cannot be used to 
predict treatment efficacy, as is often assumed. In a 
similar study, Kobus et al. reported that only a 
subgroup of the treated animals had therapeutic 
benefit of BBB-opening [40]. In our histology sections 
we did not observe any down-regulation of P-gp in 
the FUS treated regions as observed by others [13-16]. 
However, the animals were killed 4 weeks after the 
last treatment and the stained sections can therefore 
not disclose anything on temporary effects short time 
after FUS treatment. 
The accumulation of cab in the tumor 
hemisphere was around four times higher than in the 
healthy hemisphere in all treatment groups. This 
means that cab in its clinical formulation, as well as 
when combined with FUS and MBs, either free or 
encapsulated, crosses the BTB at least 4 times more 
efficiently (since the tumor does not cover the whole 
hemisphere) than the BBB. While there were rather 
large individual differences in cab accumulation 
between the animals, there was a striking correlation 
between magnitude of cab accumulation in the 
healthy hemisphere, and the hemisphere with the 
tumor implanted. This suggests that other factors than 
disease progression and BTB status have effects on the 
delivery of cab (and probably multiple other drugs) to 
the brain and P-gp expression might be such a factor.  
The PDX disease model used was chosen due to 
its invasive phenotype and independecy of 
angiogenesis [26], suggesting an intact BTB. The 
integrity of BTB before and after FUS was verified by 
a bolus injection of Gd, and no indications of leaky 
BTB was found before FUS treatment. As we have also 
seen in previous experiments, the BBB could be 
opened with FUS allowing for accumulation of Gd in 
the sonicated region [25]. This shows that the tumor 
model exhibited a mainly intact BTB and the effect of 
FUS with respect to Gd extravasation was similar to 
what we have observed for the BBB in healthy 
animals. Our study shows that successful opening of 
the BTB is not required to achieve a therapeutic effect 
of the drug alone. However, there are several studies 
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demonstrating that drug delivery to the brain and 
brain tumors is hampered by the BBB/BTB and that 
opening the barrier with sonopermeation will increase 
the delivery [12, 41]. Our results show that all 
treatment groups performed similarly, but better than 
the control, and indicate that this is a field where more 
fundamental research is necessary to understand the 
underlying processes and effects. Our work indicates 
that opening of the BBB/BTB is not sufficient for 
improving the therapeutic response, but also the 
efflux pumps represent a major barrier for the drug. 
Another important implication from this study is 
that invasive tumors, even low or non-angiogenic, can 
change the properties of the surrounding vasculature 
significantly as seen by reduction of P-gp expression. 
As our study is performed in a model from a single 
patient we cannot conclude on the generality of this 
observation. Future work should investigate if this 
occurs also in other GBM models and in patients with 
GBM. 
While the lack of therapeutic gains from 
BBB/BTB opening by sonopermeation is surprising, 
our study shows that cab had a significant effect on 
the therapeutic response for this tumor model and is a 
drug that should be evaluated and considered in more 
detail for medication of brain tumors. We did not find 
increased therapeutic benefit from encapsulation in 
NPs, but nano-encapsulation could reduce the toxic 
effects of cab and be a useful alternative to the clinical 
formulation. Although our study lacks the 
comparison to standard of care and can therefore not 
be used to compare the effect of various treatments, it 
should be highlighted that invasive brain tumors are 
among the hardest to treat and any drug that can 
significantly slow the growth of these tumors are 
interesting candidates. 
Conclusion 
We have shown that non-angiogenic tumors can 
alter the expression of P-gp in the BTB and that this 
alteration is significant for accumulation of cab in the 
brain. Furthermore, we have shown that cab can 
reduce growth of a GBM PDX-tumor model, and this 
works for both free drug without FUS induced 
BTB-opening and for NPs with FUS induced 
BTB-opening. That NPs can be used to treat tumors in 
the brain with the same efficacy as normally 
formulated drug could be used to reduce the dose 
limiting side-effects often seen from cab.  
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